Geneva Advisors’s Novartis NVS Stock Holding History

Geneva Advisors’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$1.91M	Sell	25,532 -688	-3%	-$48.8K	0.03%	227
2017 Q1	$1.75M	Sell	26,220 -6,234	-19%	-$415K	0.03%	238
2016 Q4	$2.12M	Sell	32,454 -1,523	-4%	-$98.8K	0.04%	199
2016 Q3	$2.4M	Buy	33,977 +1,036	+3%	+$75.5K	0.05%	175
2016 Q2	$2.44M	Sell	32,941 -1,966	-6%	-$136K	0.05%	173
2016 Q1	$2.27M	Sell	34,907 -292	-0.8%	-$19.9K	0.05%	172
2015 Q4	$2.71M	Buy	35,199 +673	+2%	+$53.5K	0.05%	158
2015 Q3	$2.84M	Buy	34,526 +3,048	+10%	+$271K	0.06%	154
2015 Q2	$2.77M	Buy	31,478 +3,326	+12%	+$305K	0.05%	175
2015 Q1	$2.49M	Sell	28,152 -4,143	-13%	-$367K	0.05%	187
2014 Q4	$2.68M	Sell	32,295 -4,154	-11%	-$344K	0.05%	172
2014 Q3	$3.07M	Sell	36,449 -1,624	-4%	-$131K	0.06%	167
2014 Q2	$3.09M	Buy	38,073 +4,649	+14%	+$366K	0.06%	169
2014 Q1	$2.55M	Buy	33,424 +8,745	+35%	+$637K	0.05%	185
2013 Q4	$1.78M	Buy	24,679 +474	+2%	+$32.9K	0.03%	171
2013 Q3	$1.66M	Sell	24,205 -69	-0.3%	-$4.57K	0.03%	180
2013 Q2	$1.54M	Buy	+24,274	New	+$1.58M	0.04%	174

Other funds holding NVS

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $22.8B AUM 25.09% 1-Year Est. Return

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geneva Advisors's NVS Position: Q2 2017 in Review

Geneva Advisors reduced its Novartis (NVS) stake by 2.6% in Q2 2017, selling an estimated $48.8K and leaving 25,532 shares worth $1.91M. The position accounts for 0.03% of the portfolio, ranked #227.

Geneva Advisors first reported a position in NVS in Q2 2013 and has held it in 17 quarters since. The position peaked at $3.09M in Q2 2014. 921 funds tracked by Wall St. Rank hold NVS as of Q2 2017.

Geneva Advisors held 25,532 shares of Novartis worth $1.91M as of Q2 2017.
Geneva Advisors sold 688 Novartis shares in Q2 2017, an estimated $48.8K.
Novartis made up 0.03% of Geneva Advisors's portfolio in Q2 2017, its #227 holding.
Geneva Advisors first reported a position in Novartis in Q2 2013 and has held it in 17 quarters since.
Geneva Advisors's Novartis position peaked at $3.09M in Q2 2014.
921 funds tracked by Wall St. Rank held Novartis as of Q2 2017.

Based on Geneva Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.